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Introduction {#cam4757-sec-0001}
============

Breast cancer is the most common cancer diagnosed in women in the United States, accounting for 29% of newly diagnosed female cancers. An estimated 246,660 new cases and 40,450 deaths are anticipated from the disease in 2016 [1](#cam4757-bib-0001){ref-type="ref"}. Breast cancer most commonly arises from the mammary ductal epithelium, and its systemic treatment is guided by its molecular characteristics. Specifically, National Comprehensive Care Network (NCCN) guidelines for the treatment of invasive breast cancer outline systemic adjuvant therapies based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) statuses, where positive HR status is defined as expression of the estrogen (ER) and/or progesterone (PR) receptors [2](#cam4757-bib-0002){ref-type="ref"}. Clinically, tumor cells are evaluated for these biological markers to approximate cancer molecular subtype based on expression profiling (Luminal A/B, HER2−enriched, basal‐like).

Luminal breast cancers account for about 60% of all cases. They are HR‐positive (HR+) and can be further classified based on HER2 receptor status [3](#cam4757-bib-0003){ref-type="ref"}. Luminal A breast cancers are HER2−negative (HR+/HER2−) and include ER+/PR+, ER+/PR−, and ER−/PR+ status. Their adjuvant treatment includes endocrine therapy with or without multimodality chemotherapy, based on tumor size, lymph node status, and, more recently, the 21‐gene recurrence score [2](#cam4757-bib-0002){ref-type="ref"}. In contrast, Luminal B tumors tend to be more aggressive, demonstrate HER2−enrichment (HR+/HER2+), and encompass ER+/PR+, ER+/PR−, and ER−/PR+ cases. Recommended treatment for Luminal B tumors includes anthracycline‐based trastuzumab‐containing multimodality chemotherapy, followed by a 1‐year course of trastuzumab and 5 years of endocrine therapy [2](#cam4757-bib-0002){ref-type="ref"}. Together, luminal breast cancer subtypes are associated with the best short‐term prognoses for patients, attributable to favorable responses to hormonal therapy [4](#cam4757-bib-0004){ref-type="ref"}, [5](#cam4757-bib-0005){ref-type="ref"}.

Across breast cancer subtypes, there exist demographic and socioeconomic status (SES) differences [6](#cam4757-bib-0006){ref-type="ref"}. Previous reports have found that differences in SES may reflect underlying differences in exposures to known breast cancer risk factors, as women with higher SES tended to have lower parity and more frequent use of exogenous hormones [7](#cam4757-bib-0007){ref-type="ref"}, [8](#cam4757-bib-0008){ref-type="ref"}, [9](#cam4757-bib-0009){ref-type="ref"}. Additionally, SES has been found to interact with race/ethnicity among female breast cancers [10](#cam4757-bib-0010){ref-type="ref"}. SES has previously been associated with negative HR status (HER2−enriched and basal‐like subtypes) in breast cancer [7](#cam4757-bib-0007){ref-type="ref"}, [11](#cam4757-bib-0011){ref-type="ref"}, [12](#cam4757-bib-0012){ref-type="ref"}. SES disparities have also persisted in HR+ subtypes (HR+/HER2− and HR+/HER2+) [13](#cam4757-bib-0013){ref-type="ref"}. We therefore sought to explore further clinical and demographic differences in order to identify disparities among female patients with luminal (HR+) breast cancer subtypes using Surveillance, Epidemiology, and End Results (SEER) data by assessing estrogen and progesterone receptor status, and the role of SES in risk of disease.

Methods {#cam4757-sec-0002}
=======

Data sources and case selection {#cam4757-sec-0003}
-------------------------------

Data were obtained from the National Cancer Institute\'s SEER program. The SEER program collects cancer incidence and mortality data from 20 population‐based cancer registries covering approximately 28% of the US population [14](#cam4757-bib-0014){ref-type="ref"}. SEER\*Stat is a free program provided by SEER to access and analyze information in the publicly available database. A case listing session in SEER\*Stat was run on the SEER 18 incidence dataset to obtain demographic, tumor characteristics, and socioeconomic information on breast cancers [15](#cam4757-bib-0015){ref-type="ref"}. The SEER 18 incidence dataset includes information from the following registries: Alaska Native Tumor Registry, Arizona Indians, Cherokee Nation, Connecticut, Detroit, Atlanta, Greater Georgia, Rural Georgia, San Francisco‐Oakland, San Jose‐Monterey, Greater California, Hawaii, Iowa, Kentucky, Los Angeles, Louisiana, New Jersey, New Mexico, Seattle‐Puget Sound, and Utah. The dataset used is publicly available and was exempt from human subjects review. Therefore, an IRB protocol was not required for this study.

Women with invasive breast cancer diagnosed from 2010 to 2012 were included in this study. Diagnosis year 2010 is the first year for which HER2 status data were available. Study data, including ER, PR, and HER2 status, demographic characteristics, and tumor stage, were identified across SEER registries using standardized coding rules based on pathology reports and hospital medical records. Case patients diagnosed with nevi and melanomas; soft tissue tumors and sarcomas, NOS; fibromatous neoplasms; lipomatous neoplasms; myomatous neoplasms; fibroepithelial neoplasms; synovial‐like neoplasms; blood vessel tumors; osseous and chondromatous neoplasms; miscellaneous bone tumors; gliomas; nerve sheath tumors; and granular cell tumors and alveolar soft part sarcoma histologies were excluded. To assess breast cancer subtype, tumors were classified into six mutually exclusive categories: ER+/PR+/HER2−; ER+/PR−/HER2−; ER−/PR+/HER2−; ER+/PR+/HER2+; ER+/PR−/HER2+; ER−/PR+/HER2+. We restricted our analyses to exclude patients without positive/negative ER, PR, or HER2 statuses (*n* = 19,020). Case patients with ER−/PR−/HER2+ (HER2−enriched) and ER−/PR−/HER2− (Basal‐like) receptor status were also excluded (*n* = 26,736). The final analytic dataset consisted of 134,639 breast cancer patients.

The variables of interest included age at diagnosis (\<50, 50--64, 65--74, 75+ years), race/ethnicity (non‐Hispanic (NH) white, NH black, NH Asian, or Pacific Islander, NH American Indian, Hispanic), American Joint Commission of Cancer (AJCC) clinical stage, and tumor size (≤0.5 cm, \>0.5 cm). An approximation of SES was evaluated using contextual measures of area‐based poverty. The percentage of persons and families whose incomes were below 200% of the poverty level were calculated in SEER using county attribute data from the US Census Bureau\'s 2008--2012 American Community Survey. We categorized our cohort of breast cancer cases into quartiles based on the percentage of persons with incomes below 200% of the poverty level distribution within the dataset. Quartile 1 (Q1) (\<24%) represented the fourth of the cohort that reside in areas where less than 24% of residents are from low‐income category. We defined quartile 2 (Q2) (24% ≤ 31% low income), quartile 3 (Q3) (31% ≤ 39%), and quartile 4 (Q4) (\>39%), such that Q4 contained the fourth of our cohort that reside in areas with the highest proportion of low‐income residents. Follow‐up for each case was current within 22 months of the annual submission date (1 November 2014).

Statistical analysis {#cam4757-sec-0004}
--------------------

Pair‐wise comparisons of hormone receptor (HR) categories by demographic and tumor characteristics were examined using chi‐squared tests. Multinomial logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) to quantify associations between breast cancer hormone receptor status and various demographic factors. Analyses were stratified by HER2 status and the reference outcome category was ER+/PR+ disease. Demographics variables assessed, included: age at diagnosis (\<50, 50--64, 65--74, 75+), race/ethnicity (NH white, NH black, NH Asian or Pacific Islander, NH American Indian, Hispanic), and area‐based poverty level (quartiles). These factors were adjusted for age, race/ethnicity, and poverty level based on patients having complete information for each of these covariables. All data were analyzed using SAS version 9.4 statistical software (SAS Institute; Cary, NC). All statistical tests were two‐sided. A *P *\< 0.05 was considered to be statistically significant.

Results {#cam4757-sec-0005}
=======

Differences among ER+/PR+, ER+/PR−, and ER−/PR+ hormone receptor‐positive breast cancers {#cam4757-sec-0006}
----------------------------------------------------------------------------------------

Expression of the estrogen (ER) and/or progesterone (PR) receptors was defined as hormone receptor‐positive (HR+) disease [2](#cam4757-bib-0002){ref-type="ref"}. To study the clinical, demographic, and socioeconomic differences within Luminal A (HR+/HER2−) and Luminal B (HR+/HER2+) clinical breast cancer subtypes, we gathered 134,639 patients with HR+ and known HER2 receptor status from the SEER database [6](#cam4757-bib-0006){ref-type="ref"}. Among these patients, 118,285 (87.8%) cases were HR+/HER2− (Luminal A) (Table [1](#cam4757-tbl-0001){ref-type="table-wrap"}) and 16,354 (12.2%) were HR+/HER2+ (Luminal B) tumors (Table [2](#cam4757-tbl-0002){ref-type="table-wrap"}).

###### 

Patient and tumor characteristics of Luminal A invasive breast cancer cases

                           *N*        Luminal A (HER2−)   *P*‐value[a](#cam4757-note-0003){ref-type="fn"}                                       
  ------------------------ ---------- ------------------- ------------------------------------------------- -------- ------ ------ ------ -- -- --
  Total                    118,285    102,087                                                               14,994          1204                
  Age at diagnosis         \<0.0001   \<0.0001            \<0.0001                                                                              
  \<50                     21,777     19,299              18.9                                              2081     13.9   397    33.0         
  50--64                   43,550     37,261              36.5                                              5849     39.0   440    36.5         
  65--74                   28,705     24,836              24.3                                              3670     24.5   199    16.5         
  ≥75                      24,253     20,691              20.3                                              3394     22.6   168    14.0         
  Race/ethnicity           \<0.0001   \<0.0001            \<0.0001                                                                              
  NH white                 85,717     74,701              73.2                                              10,297   68.7   719    59.7         
  NH black                 10,540     8371                8.2                                               1930     12.9   239    19.9         
  Asian/Pacific Islander   9117       7956                7.8                                               1094     7.3    67     5.6          
  Am.Indian/AlaskaNative   633        555                 0.5                                               71       0.5    7      0.6          
  Hispanic                 11,429     9766                9.6                                               1496     10.0   167    13.9         
  Unknown                  849        738                 0.7                                               106      0.7    5      0.4          
  AJCC stage               \<0.0001   \<0.0001            \<0.0001                                                                              
  0--I                     64,491     57,029              55.9                                              7018     46.8   444    36.9         
  II                       34,905     29,601              29.0                                              4809     32.1   495    41.1         
  III                      11,352     9329                9.1                                               1868     12.5   155    12.9         
  IV                       4979       3997                3.9                                               900      6.0    82     6.8          
  Unknown                  2558       2131                2.1                                               399      2.7    28     2.3          
  Tumor size               0.1503     \<0.0001            \<0.0001                                                                              
  ≤0.5 cm                  10,091     8724                8.5                                               1316     8.8    51     4.2          
  \>0.5 cm                 104,379    90,257              88.4                                              13,021   86.8   1101   91.4         
  Unknown                  3815       3106                3.0                                               657      4.4    52     4.3          
  Poverty index            0.0833     \<0.0001            \<0.0001                                                                              
  Q1                       28,333     24,551              24.0                                              3516     23.4   266    22.1         
  Q2                       27,526     23,778              23.3                                              3513     23.4   235    19.5         
  Q3                       28,566     24,569              24.1                                              3736     24.9   261    21.7         
  Q4                       33,837     29,170              28.6                                              4226     28.2   441    36.6         
  Unknown                  23         19                  0.0                                               3        0.0    1      0.1          

Summary of clinical and demographic characteristics of hormone receptor‐positive (HR+), HER2− Luminal A breast cancers in women with invasive breast cancer: Surveillance, Epidemiology and End Results 18, 2010--2012. NH, non‐Hispanic; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

*P*‐value calculations do not include unknown values.
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###### 

Patient and tumor characteristics of Luminal B invasive breast cancer cases

                             *N*        Luminal B (HER2+)   *P*‐value[a](#cam4757-note-0005){ref-type="fn"}                                    
  -------------------------- ---------- ------------------- ------------------------------------------------- ------ ------ ----- ------ -- -- --
  Total                      16,354     11,391                                                                4491          472                
  Age at diagnosis           \<0.0001   0.7842              \<0.0001                                                                           
  \<50                       4621       3518                30.9                                              950    21.2   153   32.4         
  50--64                     6631       4431                38.9                                              2016   44.9   184   39.0         
  65--74                     2886       1951                17.1                                              855    19.0   80    16.9         
  ≥75                        2216       1491                13.1                                              670    14.9   55    11.7         
  Race/ethnicity             0.3661     \<0.0001            \<0.0001                                                                           
  NH white                   10,793     7545                66.2                                              2970   66.1   278   58.9         
  NH black                   1918       1306                11.5                                              555    12.4   57    12.1         
  Asian/Pacific Islander     1491       1038                9.1                                               400    8.9    53    11.2         
  Am. Indian/Alaska Native   105        63                  0.6                                               30     0.7    12    2.5          
  Hispanic                   1921       1352                11.9                                              503    11.2   66    14.0         
  Unknown                    126        87                  0.8                                               33     0.7    6     1.3          
  AJCC stage                 \<0.0001   \<0.0001            0.003                                                                              
  0--I                       6383       4534                39.8                                              1710   37.9   139   29.2         
  II                         5792       4073                35.8                                              1536   34.2   183   38.8         
  III                        2463       1697                14.9                                              676    15.1   90    19.1         
  IV                         1260       781                 6.9                                               437    9.7    42    8.9          
  Unknown                    456        306                 2.7                                               132    2.9    18    3.8          
  Tumor size                 \<0.0001   0.1152              0.7848                                                                             
  ≤0.5 cm                    1348       861                 7.6                                               443    9.9    44    9.3          
  \>0.5 cm                   14,178     9983                87.6                                              3800   84.6   395   83.7         
  Unknown                    828        547                 4.8                                               248    5.5    33    7.0          
  Poverty index              0.1446     0.6807              0.3295                                                                             
  Q1                         3648       2514                22.1                                              1025   22.8   109   23.1         
  Q2                         3717       2585                22.7                                              1030   22.9   102   21.6         
  Q3                         3814       2635                23.1                                              1078   24.0   101   21.4         
  Q4                         5172       3654                32.1                                              1358   30.2   160   33.9         
  Unknown                    3          3                   0.0                                               0      0.0    0     0.0          

Summary of clinical and demographic characteristics of hormone receptor‐positive (HR+), HER2+ Luminal B breast cancers in women with invasive breast cancer: Surveillance, Epidemiology and End Results 18, 2010--2012. NH, non‐Hispanic; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

*P*‐value calculations do not include unknown values.
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For Luminal A (HR+/HER2−) cases, 102,087 (86.3%) were ER+/PR+; 14,994 (12.7%) ER+/PR−; and 1204 (1.0%) ER−/PR+ (Table [1](#cam4757-tbl-0001){ref-type="table-wrap"}). Luminal A subtype patients demonstrated significantly different distributions by age, race/ethnicity, tumor size, AJCC clinical stage, and SES measures of poverty (*P* \< 0.0001). Specifically, Luminal A cases with ER−/PR+ status were more likely to be diagnosed at a younger age, to be NH black or Hispanic, to live in counties with higher poverty, to have larger tumors, and to present with later stage disease (Table [1](#cam4757-tbl-0001){ref-type="table-wrap"}).

Of the Luminal B (HR+/HER2+) tumors, 11,391 (69.7%) were ER+/PR+; 4491 (27.4%) ER+/PR−; and 472 (2.9%) ER−/PR+ (Table [2](#cam4757-tbl-0002){ref-type="table-wrap"}). Patients with Luminal B breast cancers had distributions that varied by age, race/ethnicity, and AJCC clinical stage. Compared with ER+/PR− and ER+/PR+ patients, Luminal B cases with ER−/PR+ status were more likely to be diagnosed at a younger age, to be NH Asian, Pacific Islander, or Hispanic, and to be diagnosed at later stages of disease (Table [2](#cam4757-tbl-0002){ref-type="table-wrap"}). Among Luminal B tumors, we observed no significant differences in SES, measured with county‐level poverty (*P* = 0.1446, *P* = 0.6807, and *P* = 0.3295).

An additional 19,020 breast cancer patients had borderline or unknown status for ER, PR, or HER2, and were not included in this analysis. Among these women, 67.7% were NH white (12,876 cases), 11.7% were NH black (2227 cases), 10.9% were Hispanic (2068 cases), 7.4% were Asian or Pacific Islander (1404 cases), 0.5% were American Indian/Alaska Native (91 cases), and 1.9% (354 cases) had unknown race/ethnicity (data not shown). Eighty three percent of unknown cases were diagnosed with invasive breast cancer at age 50 years and older (15,793 cases). 61.5% of cases were diagnosed with early stage (AJCC stage 0--II) disease (11,701 cases), 17.8% were diagnosed with later stage (AJCC stage III--IV) cancer, and 20.1% (3929 cases) did not have information on AJCC stage. 59.1% of cases (11,242 cases) resided in areas where at least 31% of residents were living in poverty (Q3 or Q4). Together, cases with unknown receptor status tended to be NH white, older, and diagnosed with early‐stage disease (data not shown).

Overall, we observed that, regardless of HER2 status, ER−/PR+ cases were more likely to be diagnosed in young patients (age \<50 years) and to present with later stage (stage III--IV) disease, but were less likely to be NH white, as compared to ER+/PR− or ER+/PR+ patients.

Socioeconomic disparities in Luminal A breast cancers {#cam4757-sec-0007}
-----------------------------------------------------

We also noted significant differences in area‐based poverty among patients with Luminal A (HR+/HER2−) tumors. To further explore the relationship of SES and HR+ status (ER+/PR+, ER+/PR−, or ER−/PR+) within each breast cancer subtype, we used multinomial logistic regression models. Because race and age are associated with SES, we adjusted for these variables to determine whether socioeconomic disparities persisted in this population.

Table [3](#cam4757-tbl-0003){ref-type="table-wrap"} summarizes results from models adjusted for area‐based poverty, age, and race/ethnicity. Using ER+/PR+ tumors as the referent outcome in each subtype and poverty quartile Q1 as the referent covariable, we found that women with Luminal A breast cancer who live in counties with higher poverty were more likely to be diagnosed with ER−/PR+ disease (Q4: OR = 1.20, 95% CI = 1.03--1.40) (Table [3](#cam4757-tbl-0003){ref-type="table-wrap"}). Women diagnosed with ER−/PR+ Luminal A disease were 1.7‐fold more likely to be under 50 years of age compared to women with ER+/PR+ tumors in our area‐based poverty‐adjusted models. In addition, NH blacks were at an increased risk of being diagnosed with ER−/PR+ Luminal A breast cancers (OR = 2.62, 95% CI = 2.25--3.05). Notably, age, race, and poverty were not associated with ER−/PR+ disease in Luminal B breast cancers (Table [3](#cam4757-tbl-0003){ref-type="table-wrap"}).

###### 

Adjusted odds ratios (OR) for patient demographics and socioeconomic status by hormone receptor‐positive (HR+) breast cancers

                                                   Area‐based poverty[a](#cam4757-note-0007){ref-type="fn"}                                           
  ------------------------------------------------ ---------------------------------------------------------- ------------------- ------------------- -------------------
  Age at diagnosis                                                                                                                                    
  \<50                                             0.67 (0.64--0.71)                                          1.68 (1.47--1.93)   0.59 (0.54--0.65)   1.01 (0.81--1.26)
  50--64[d](#cam4757-note-0010){ref-type="fn"}     1                                                          1                   1                   1
  65--74                                           0.96 (0.91--1.00)                                          0.70 (0.59--0.82)   0.97 (0.88--1.07)   0.99 (0.75--1.29)
  ≥75                                              1.08 (1.03--1.13)                                          0.72 (0.60--0.86)   1.01 (0.90--1.12)   0.94 (0.69--1.28)
  Race/ethnicity                                                                                                                                      
  NH white[d](#cam4757-note-0010){ref-type="fn"}   1                                                          1                   1                   1
  NH black                                         1.75 (1.66--1.85)                                          2.62 (2.25--3.05)   1.14 (1.02--1.28)   1.18 (0.88--1.58)
  Asian/Pacific Islander                           1.05 (0.98--1.12)                                          0.77 (0.59--0.99)   1.03 (0.91--1.17)   1.36 (1.00--1.84)
  Am. Indian/Alaska Native                         0.96 (0.75--1.23)                                          1.22 (0.57--2.57)   1.27 (0.82--1.97)   5.15 (2.74--9.67)
  Hispanic                                         1.19 (1.12--1.26)                                          1.48 (1.25--1.76)   1.04 (0.93--1.16)   1.31 (0.99--1.73)
  Poverty index                                                                                                                                       
  Q1[d](#cam4757-note-0010){ref-type="fn"}         1                                                          1                   1                   1
  Q2                                               1.02 (0.97--1.07)                                          0.89 (0.75--1.07)   0.96 (0.87--1.07)   0.90 (0.68--1.19)
  Q3                                               1.01 (0.96--1.06)                                          0.88 (0.74--1.05)   0.97 (0.88--1.08)   0.88 (0.66--1.16)
  Q4                                               0.93 (0.89--0.98)                                          1.20 (1.03--1.40)   0.88 (0.79--0.97)   0.98 (0.76--1.27)

NH, non‐Hispanic; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

Model adjusted for age, race, and poverty (quartiles).

Referent group is HER2−/ER+/PR+.

Referent group is HER2+/ER+/PR+.

Referent covariable.
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Discussion {#cam4757-sec-0008}
==========

In this study, we explored associations among luminal breast cancers and SES as assessed by age, race/ethnicity, and a measurement of county‐level poverty and found that within Luminal A (HR+/HER2−) and Luminal B (HR+/HER2+) cancers, clinical and demographic characteristics varied. Clinical differences among luminal breast cancers can be attributed to the opposing effects of estrogen and progesterone on tumor progression. Estrogen supports tumor growth but suppresses progression, whereas, progesterone supports tumor progression and is associated with more aggressive disease [16](#cam4757-bib-0016){ref-type="ref"}, [17](#cam4757-bib-0017){ref-type="ref"}. In the absence of estrogen signaling (ER− tumors), high progesterone levels in women have been shown to support tumor progression without opposition from estrogen [18](#cam4757-bib-0018){ref-type="ref"}, [19](#cam4757-bib-0019){ref-type="ref"}. Consistent with these findings, we observed in this study that regardless of HER2 status, women with ER−/PR+ tumors were more likely to present with later stage (stage III--IV) disease compared to ER+/PR+ or ER+/PR− cases. These results suggest that differences in HR+ (ER−/PR+ vs. ER+/PR− or ER+/PR+) tumor biology are likely to be clinically significant and play a role in breast cancer disease, regardless of HER2 status.

Demographic characteristics of patients, including age, also varied within each luminal breast cancer subtype. Progesterone levels are higher in premenopausal women, typically those diagnosed with breast cancer under the age of 50 years, compared to postmenopausal women over the age of 60 [20](#cam4757-bib-0020){ref-type="ref"}, [21](#cam4757-bib-0021){ref-type="ref"}. Our study showed that women under the age of 50 were at an increased risk of developing ER−/PR+ Luminal A disease, while women over the age of 60 were at a decreased risk compared to ER+/PR+ disease. This observation is consistent with reports that high progesterone levels (occurring only in the luteal phase and in pregnancy) will induce breast cancer cell invasiveness and metastasis in the absence of estrogen or the ER. In contrast, age was not associated with increased risk of ER−/PR+ disease among Luminal B cases. This observation may be explained by findings using experimental models, that overexpression of HER2 supports aggressive tumor growth in luminal breast cancers [22](#cam4757-bib-0022){ref-type="ref"}.

Racial and ethnic differences were also noted among Luminal A cancers, as NH black women were most likely to develop ER−/PR+ disease. Indeed, previous studies have demonstrated that among Luminal A tumors, race‐associated biological factors contribute to poorer outcomes in black women compared to NH white women [23](#cam4757-bib-0023){ref-type="ref"}, [24](#cam4757-bib-0024){ref-type="ref"}. Among women with Luminal B tumors, NH Asian or Pacific Islander or American Indian/Alaska Native individuals were at an increased risk of developing ER−/PR+ tumors. However, caution should be taken in interpreting results in these racial/ethnic categories due to small sample size. Earlier findings have observed that Hispanic white women are more likely to present with more aggressive tumors and be diagnosed with ER+/PR− disease [25](#cam4757-bib-0025){ref-type="ref"}. In our study, we confirmed that Hispanic individuals were at an increased risk of developing ER+/PR− or ER−/PR+ disease compared to ER+/PR+ status in both Luminal A and B breast cancer subtypes after adjusting for age, race, and area‐based poverty.

While clinical and patient characteristics differed within each luminal breast cancer subtype, we found disparities in SES persist only among Luminal A tumors. Luminal A breast cancers are associated with the most favorable short‐term prognosis due to favorable responses to endocrine therapy [4](#cam4757-bib-0004){ref-type="ref"}, [5](#cam4757-bib-0005){ref-type="ref"}. However, assessment of long‐term prognosis demonstrates similar or worse overall survival for Luminal A cases as compared to other subtypes [26](#cam4757-bib-0026){ref-type="ref"}. In our study, among Luminal A cases, we observed that ER−/PR+ disease was associated with residing in areas of higher poverty even after adjusting for age and race/ethnicity. Caution should be exercised in the interpretation for results of ER−/PR+ cases due to small sample size. The relationship between SES and development of Luminal A breast cancers demonstrates that while race and SES are correlated, each plays an independent role in contributing to disease among Luminal A tumors. These disparities were not observed among Luminal B tumors, suggesting that HER2 status may be associated with risk factors that affect the SES of patients.

Our study is the first to assess disparities among HR‐positive (HR+) breast cancer subtypes in the context of HER2 status using SEER patient data. Previous studies have investigated the role of HR+ status without HER2 information, or have analyzed the role by breast cancer subtype. For example, a recent study by Parise et al. that used the California Cancer Registry found that SES moderately altered racial disparities and risk of mortality in particular breast cancer subtypes [27](#cam4757-bib-0027){ref-type="ref"}. Similar results have been observed among other tumor sites [10](#cam4757-bib-0010){ref-type="ref"}. While our findings suggest differences within Luminal A or B breast cancer subtypes, available data for HER2 are limited to 3 years of diagnosis, which does not allow further analysis for SES disparities in mortality at this time. The use of data from the population‐based SEER program is a strength of this study, as it allows for the inclusion of a considerable number of pathologically verified cases making our results more generalizable to the larger United States population. Another strength is that these data are of high quality and database entries are standardized and continuously monitored for accuracy. However, use of SEER data does have limitations. Family history, lifestyle‐related factors (e.g., obesity, reproductive factors, and environmental exposures), modality of diagnosis, and chemotherapy data, are not available for study. We were also unable to examine patients whose ER, PR, or HER2 status was unknown.

Scientific, clinical, and public health implications can be inferred from this study. First, our findings are consistent with preclinical and clinical data regarding the opposing effects of the estrogen and progesterone receptors in breast cancer growth and progression. Further research is needed to analyze the opposing effects of hormone receptors in the context of HER2 status. Hormone receptor‐positive (HR+) breast cancers are currently defined as ER and/or PR‐positive tumors. In addition, our observations suggest that additional work is required to assess clinical differences we observed, particularly between ER−/PR+ and ER+/PR− breast cancers, as this information could potentially be used to improve systemic adjuvant treatments. Disparities in SES among Luminal A (HR+/HER2−) breast cancer patients may be associated with risks of recurrence and mortality, and identifying barriers in patient access to medical care can seek to improve patient outcomes in underserved, high‐risk populations. Overall, detailed investigations of differences in tumor biology and association of race/ethnicity and SES among HR‐positive breast cancers, particularly those with HER2−negative status (HR+/HER2−), may lead to the identification of additional prognostic markers, direct resources to underserved populations for screening, and improve adjuvant treatments to better long‐term patient outcomes.
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